Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Inflammatory signatures distinguish metabolic health in African American women with obesity.

Denis GV, Sebastiani P, Bertrand KA, Strissel KJ, Tran AH, Slama J, Medina ND, Andrieu G, Palmer JR.

PLoS One. 2018 May 8;13(5):e0196755. doi: 10.1371/journal.pone.0196755. eCollection 2018.

2.

BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.

Andrieu GP, Shafran JS, Deeney JT, Bharadwaj KR, Rangarajan A, Denis GV.

J Leukoc Biol. 2018 Mar 1. doi: 10.1002/JLB.5RI0917-380RR. [Epub ahead of print] Review.

PMID:
29493812
3.

BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.

Andrieu GP, Denis GV.

Mol Cancer Res. 2018 Apr;16(4):580-586. doi: 10.1158/1541-7786.MCR-17-0568. Epub 2018 Feb 7.

PMID:
29437854
4.

Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.

Palmer JR, Castro-Webb N, Bertrand K, Bethea TN, Denis GV.

Cancer Res. 2017 Nov 15;77(22):6462-6469. doi: 10.1158/0008-5472.CAN-17-1903.

PMID:
29141994
5.

Relationships Among Obesity, Type 2 Diabetes, and Plasma Cytokines in African American Women.

Denis GV, Sebastiani P, Andrieu G, Tran AH, Strissel KJ, Lombardi FL, Palmer JR.

Obesity (Silver Spring). 2017 Nov;25(11):1916-1920. doi: 10.1002/oby.21943. Epub 2017 Aug 25.

6.

"Obesity-Associated" Breast Cancer in Lean Women: Metabolism and Inflammation as Critical Modifiers of Risk.

Denis GV, Palmer JR.

Cancer Prev Res (Phila). 2017 May;10(5):267-269. doi: 10.1158/1940-6207.CAPR-17-0083. Epub 2017 Apr 13.

7.

Diabetes and breast cancer mortality in Black women.

Charlot M, Castro-Webb N, Bethea TN, Bertrand K, Boggs DA, Denis GV, Adams-Campbell LL, Rosenberg L, Palmer JR.

Cancer Causes Control. 2017 Jan;28(1):61-67. doi: 10.1007/s10552-016-0837-z. Epub 2016 Dec 19.

8.

BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.

Andrieu G, Tran AH, Strissel KJ, Denis GV.

Cancer Res. 2016 Nov 15;76(22):6555-6567. doi: 10.1158/0008-5472.CAN-16-0559. Epub 2016 Sep 20.

9.

Clinical trials for BET inhibitors run ahead of the science.

Andrieu G, Belkina AC, Denis GV.

Drug Discov Today Technol. 2016 Mar;19:45-50. doi: 10.1016/j.ddtec.2016.06.004. Epub 2016 Jul 21. Review.

10.

Correction to "Barriers to Obtaining Sera and Tissue Specimens of African-American Women for the Advancement of Cancer Research".

Strissel KJ, Nicholas DA, Castagne-Charlotin M, Ko N, Denis GV.

Clin Med Insights Womens Health. 2016 Sep 13;9:35. eCollection 2016.

11.

BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.

Nicholas DA, Andrieu G, Strissel KJ, Nikolajczyk BS, Denis GV.

Cell Mol Life Sci. 2017 Jan;74(2):231-243. doi: 10.1007/s00018-016-2320-0. Epub 2016 Aug 4. Review.

12.

Barriers to Obtaining Sera and Tissue Specimens of African-American Women for the Advancement of Cancer Research.

Strissel KJ, Nicholas DA, Castagne-Charlotin M, Ko N, Denis GV.

Clin Med Insights Womens Health. 2016 Jul 14;9(Suppl 1):57-61. doi: 10.4137/CMWH.S34698. eCollection 2016. Erratum in: Clin Med Insights Womens Health. 2016 Sep 13;9:35.

13.

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.

Deeney JT, Belkina AC, Shirihai OS, Corkey BE, Denis GV.

PLoS One. 2016 Mar 23;11(3):e0151329. doi: 10.1371/journal.pone.0151329. eCollection 2016.

14.

Associations between metabolic disorders and risk of cancer in Danish men and women--a nationwide cohort study.

Berger SM, Gislason G, Moore LL, Andersson C, Torp-Pedersen C, Denis GV, Schmiegelow MD.

BMC Cancer. 2016 Feb 22;16:133. doi: 10.1186/s12885-016-2122-7.

15.

Immune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease.

Strissel KJ, Denis GV, Nikolajczyk BS.

Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):330-8. doi: 10.1097/MED.0000000000000085. Review.

16.

Metabolic health reduces risk of obesity-related cancer in framingham study adults.

Moore LL, Chadid S, Singer MR, Kreger BE, Denis GV.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2057-65. doi: 10.1158/1055-9965.EPI-14-0240. Epub 2014 Jul 10.

17.

Intrinsic Sex-Linked Variations in Osteogenic and Adipogenic Differentiation Potential of Bone Marrow Multipotent Stromal Cells.

Bragdon B, Burns R, Baker AH, Belkina AC, Morgan EF, Denis GV, Gerstenfeld LC, Schlezinger JJ.

J Cell Physiol. 2015 Feb;230(2):296-307. doi: 10.1002/jcp.24705.

18.

Metabolic disease risk in children by salivary biomarker analysis.

Goodson JM, Kantarci A, Hartman ML, Denis GV, Stephens D, Hasturk H, Yaskell T, Vargas J, Wang X, Cugini M, Barake R, Alsmadi O, Al-Mutawa S, Ariga J, Soparkar P, Behbehani J, Behbehani K, Welty F.

PLoS One. 2014 Jun 10;9(6):e98799. doi: 10.1371/journal.pone.0098799. eCollection 2014.

19.

The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis.

Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV.

J Leukoc Biol. 2014 Mar;95(3):451-60. doi: 10.1189/jlb.1112588. Epub 2013 Dec 6.

20.

Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.

Chung J, Karkhanis V, Tae S, Yan F, Smith P, Ayers LW, Agostinelli C, Pileri S, Denis GV, Baiocchi RA, Sif S.

J Biol Chem. 2013 Dec 6;288(49):35534-47. doi: 10.1074/jbc.M113.510669. Epub 2013 Nov 4.

21.

Healthy obese persons: how can they be identified and do metabolic profiles stratify risk?

Denis GV, Hamilton JA.

Curr Opin Endocrinol Diabetes Obes. 2013 Oct;20(5):369-76. doi: 10.1097/01.med.0000433058.78485.b3. Review.

22.

B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile.

DeFuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, Markham D, Strissel KJ, Watkins AA, Zhu M, Allen J, Bouchard J, Toraldo G, Jasuja R, Obin MS, McDonnell ME, Apovian C, Denis GV, Nikolajczyk BS.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5133-8. doi: 10.1073/pnas.1215840110. Epub 2013 Mar 11.

23.

BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.

Belkina AC, Nikolajczyk BS, Denis GV.

J Immunol. 2013 Apr 1;190(7):3670-8. doi: 10.4049/jimmunol.1202838. Epub 2013 Feb 18.

24.

Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes.

Wang F, Deeney JT, Denis GV.

Vitam Horm. 2013;91:49-75. doi: 10.1016/B978-0-12-407766-9.00003-1. Review.

25.

'Metabolically healthy obesity': origins and implications.

Denis GV, Obin MS.

Mol Aspects Med. 2013 Feb;34(1):59-70. doi: 10.1016/j.mam.2012.10.004. Epub 2012 Oct 13. Review.

26.

The outliers become a stampede as immunometabolism reaches a tipping point.

Nikolajczyk BS, Jagannathan-Bogdan M, Denis GV.

Immunol Rev. 2012 Sep;249(1):253-75. doi: 10.1111/j.1600-065X.2012.01142.x. Review.

27.

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M.

J Leukoc Biol. 2012 Dec;92(6):1147-54. doi: 10.1189/jlb.0312165. Epub 2012 Jul 16.

28.

BET domain co-regulators in obesity, inflammation and cancer.

Belkina AC, Denis GV.

Nat Rev Cancer. 2012 Jun 22;12(7):465-77. doi: 10.1038/nrc3256. Review.

29.

Parallel imaging microfluidic cytometer.

Ehrlich DJ, McKenna BK, Evans JG, Belkina AC, Denis GV, Sherr DH, Cheung MC.

Methods Cell Biol. 2011;102:49-75. doi: 10.1016/B978-0-12-374912-3.00003-1. Review.

30.
31.

Obesity genes and insulin resistance.

Belkina AC, Denis GV.

Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):472-7. doi: 10.1097/MED.0b013e32833c5c48. Review.

32.

An emerging role for bromodomain-containing proteins in chromatin regulation and transcriptional control of adipogenesis.

Denis GV, Nikolajczyk BS, Schnitzler GR.

FEBS Lett. 2010 Aug 4;584(15):3260-8. doi: 10.1016/j.febslet.2010.05.030. Epub 2010 May 21. Review.

33.

Brd2 disruption in mice causes severe obesity without Type 2 diabetes.

Wang F, Liu H, Blanton WP, Belkina A, Lebrasseur NK, Denis GV.

Biochem J. 2009 Dec 14;425(1):71-83. doi: 10.1042/BJ20090928.

34.

Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.

Romesser PB, Perlman DH, Faller DV, Costello CE, McComb ME, Denis GV.

Am J Pathol. 2009 Jul;175(1):25-35. doi: 10.2353/ajpath.2009.080707. Epub 2009 Jun 4.

35.

Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential.

Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA, Denis GV.

Int J Cancer. 2009 Jan 15;124(2):473-82. doi: 10.1002/ijc.23946.

36.

Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis.

Lenburg ME, Sinha A, Faller DV, Denis GV.

J Biol Chem. 2007 Feb 16;282(7):4803-11. Epub 2006 Dec 13.

37.

Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes.

You J, Srinivasan V, Denis GV, Harrington WJ Jr, Ballestas ME, Kaye KM, Howley PM.

J Virol. 2006 Sep;80(18):8909-19.

38.

Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines.

Denis GV, McComb ME, Faller DV, Sinha A, Romesser PB, Costello CE.

J Proteome Res. 2006 Mar;5(3):502-11.

39.

Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A.

Sinha A, Faller DV, Denis GV.

Biochem J. 2005 Apr 1;387(Pt 1):257-69.

40.

E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia.

Greenwald RJ, Tumang JR, Sinha A, Currier N, Cardiff RD, Rothstein TL, Faller DV, Denis GV.

Blood. 2004 Feb 15;103(4):1475-84. Epub 2003 Oct 16.

41.

Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras.

Denis GV, Yu Q, Ma P, Deeds L, Faller DV, Chen CY.

J Biol Chem. 2003 Feb 21;278(8):5775-85. Epub 2002 Dec 10.

42.

Bromodomain motifs and "scaffolding"?

Denis GV.

Front Biosci. 2001 Sep 1;6:D1065-8. Review.

43.

Duality in bromodomain-containing protein complexes.

Denis GV.

Front Biosci. 2001 Aug 1;6:D849-52. Review.

44.

RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F.

Denis GV, Vaziri C, Guo N, Faller DV.

Cell Growth Differ. 2000 Aug;11(8):417-24.

45.

Activation-induced nuclear translocation of RING3.

Guo N, Faller DV, Denis GV.

J Cell Sci. 2000 Sep;113 ( Pt 17):3085-91.

46.

Stimulation of p85/RING3 kinase in multiple organs after systemic administration of mitogens into mice.

Ostrowski J, Florio SK, Denis GV, Suzuki H, Bomsztyk K.

Oncogene. 1998 Mar 5;16(9):1223-7.

47.
48.
49.

The Ca2+ release activities of D-myo-inositol 1,4,5-trisphosphate analogs are quantized.

Denis GV, Ballou CE.

Cell Calcium. 1991 Jun;12(6):395-401.

PMID:
1884394
50.

Supplemental Content

Loading ...
Support Center